Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders
Pharmafile
JANUARY 5, 2023
Summary: • TMP-301 (formerly HTL0014242) is a potent, selective, and orally available mGluR5 negative allosteric modulator (NAM) candidate discovered by Sosei Heptares and out-licensed to Tempero Bio • Phase 1 study in healthy volunteers expected to begin in Q1 2023 with support from a US$5.3M read more.
Let's personalize your content